Perspectives on verteporfin therapy combined with intravitreal corticosteroids.
Schmidt-Erfurth
Ursula
U
Department of Ophthalmology, University of Vienna, Vienna, Austria. ursula.schmidt-erfurth@meduniwien.ac.at
Michels
Stephan
S
Augustin
Albert
A
D020256:Choroidal Neovascularization / Q000188:drug therapy; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D000077362:Verteporfin; D014822:Vitreous Body
D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide